<DOC>
	<DOCNO>NCT01107418</DOCNO>
	<brief_summary>This open-label study ass pharmacokinetics , efficacy safety RO5185426 administer 240mg tablet previously treat patient metastatic melanoma . Patients randomize receive one four dose-levels RO5185426 [ RG7204 ; PLEXXIKON ; PLX4032 ] orally twice daily day 1 15 ( morning dose ) . Starting day 22 , treatment RO5185426 may resume dose 960 mg twice daily continued disease progression . Target sample size &lt; 100 patient .</brief_summary>
	<brief_title>A Pharmacokinetic/Pharmacodynamic Study RO5185426 Previously Treated Patients With Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>adult patient , &gt; /=18 year age histologically confirm metastatic melanoma , stage IIIc IV ( AJCC ) failure least one prior standard care regimen positive BRAF V600E mutation ( Roche CoDx BRAF mutation assay ) ECOG performance status 0 1 adequate hematologic , renal liver function active CNS lesion CT/MRI within 28 day prior enrollment history spinal cord compression carcinomatous meningitis anticipate ongoing anticancer therapy administer study previous treatment BRAF inhibitor ( sorafenib allow ) MEK inhibitor severe cardiovascular disease within 6 month prior study previous malignancy within past 5 year except basal squamous cell carcinoma skin , melanoma insitu carcinoma insitu cervix</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>